Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968953400> ?p ?o ?g. }
- W2968953400 endingPage "6319" @default.
- W2968953400 startingPage "6309" @default.
- W2968953400 abstract "Abstract Purpose: Bromodomain and extraterminal (BET) proteins play important roles in transcriptional regulation relevant to cancer pathogenesis, and therapeutic targeting/inhibition of BET causes apoptosis of cancer cells in vitro. In this first-in-human study of the pan-BET inhibitor mivebresib (ABBV-075), the safety profile, MTD, and recommended phase II dose (RP2D) were determined in patients with advanced solid tumors. Patients and Methods: A 3 + 3 dose escalation for different mivebresib dosing schedules [daily, Monday/Wednesday/Friday (M-W-F), 4 days on/3 off (4/7)] was followed by dose expansion in patients with prostate cancer. Endpoints were safety, tolerability, pharmacokinetics, and preliminary antitumor activity. Results: Seventy-two patients with solid tumors (14% uveal melanoma; 11% colorectal; 11% breast; 8% pancreatic; 7% head/neck; 49% others) were treated with mivebresib during dose escalation, and 12 additional patients with prostate cancer in expansion cohort. Most common treatment-emergent adverse events (TEAE) related to mivebresib were dysgeusia (49%), thrombocytopenia (48%), fatigue (26%), and nausea (25%). Most common grade 3/4 TEAEs related to mivebresib were thrombocytopenia (35%) and anemia (6%). Dose-limiting toxicities included thrombocytopenia (2 mg daily; 4.5 mg M-W-F), gastrointestinal bleed (2 mg daily), hypertension (2–3 mg 4/7), fatigue, decreased appetite, and aspartate aminotransferase elevation (4 mg M-W-F). Of 61 evaluable patients from dose escalation, 26 (43%) had stable disease and 35 (57%) had progressive disease. Median progression-free survival was 1.8 months (95% confidence interval, 1.8–1.9). Conclusions: On the basis of safety and tolerability, mivebresib RP2D is 1.5 mg for the daily schedule, 2.5 mg for 4/7, and 3 mg for M-W-F. Mivebresib has a tolerable safety profile, and stable disease was observed in some patients with malignant solid tumors." @default.
- W2968953400 created "2019-08-22" @default.
- W2968953400 creator A5010925062 @default.
- W2968953400 creator A5015591858 @default.
- W2968953400 creator A5017574713 @default.
- W2968953400 creator A5035218748 @default.
- W2968953400 creator A5043585994 @default.
- W2968953400 creator A5045732752 @default.
- W2968953400 creator A5055462512 @default.
- W2968953400 creator A5056205361 @default.
- W2968953400 creator A5058733601 @default.
- W2968953400 creator A5061237827 @default.
- W2968953400 creator A5062013948 @default.
- W2968953400 creator A5064953304 @default.
- W2968953400 creator A5075799959 @default.
- W2968953400 creator A5078252133 @default.
- W2968953400 creator A5081099179 @default.
- W2968953400 date "2019-11-01" @default.
- W2968953400 modified "2023-09-30" @default.
- W2968953400 title "First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors" @default.
- W2968953400 cites W1971382122 @default.
- W2968953400 cites W1992407986 @default.
- W2968953400 cites W2002395443 @default.
- W2968953400 cites W2009949436 @default.
- W2968953400 cites W2016988770 @default.
- W2968953400 cites W2033901119 @default.
- W2968953400 cites W2041535798 @default.
- W2968953400 cites W2052692973 @default.
- W2968953400 cites W2091988355 @default.
- W2968953400 cites W2099828463 @default.
- W2968953400 cites W2109378990 @default.
- W2968953400 cites W2109790992 @default.
- W2968953400 cites W2112124155 @default.
- W2968953400 cites W2115499099 @default.
- W2968953400 cites W2116532772 @default.
- W2968953400 cites W2118428599 @default.
- W2968953400 cites W2120572492 @default.
- W2968953400 cites W2129129812 @default.
- W2968953400 cites W2138428661 @default.
- W2968953400 cites W2143432231 @default.
- W2968953400 cites W2150469988 @default.
- W2968953400 cites W2162696088 @default.
- W2968953400 cites W2226721679 @default.
- W2968953400 cites W2299219969 @default.
- W2968953400 cites W2491205940 @default.
- W2968953400 cites W2522325527 @default.
- W2968953400 cites W2522651110 @default.
- W2968953400 cites W2527196333 @default.
- W2968953400 cites W2529415134 @default.
- W2968953400 cites W2536153123 @default.
- W2968953400 cites W2558696992 @default.
- W2968953400 cites W2568322231 @default.
- W2968953400 cites W2580664298 @default.
- W2968953400 cites W2606852909 @default.
- W2968953400 cites W2611007981 @default.
- W2968953400 cites W2617353563 @default.
- W2968953400 cites W2622501844 @default.
- W2968953400 cites W2623591919 @default.
- W2968953400 cites W2738828769 @default.
- W2968953400 cites W2766688099 @default.
- W2968953400 cites W2768331219 @default.
- W2968953400 cites W2791440239 @default.
- W2968953400 cites W2793515307 @default.
- W2968953400 cites W2895961390 @default.
- W2968953400 cites W2909324552 @default.
- W2968953400 cites W2911369452 @default.
- W2968953400 doi "https://doi.org/10.1158/1078-0432.ccr-19-0578" @default.
- W2968953400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31420359" @default.
- W2968953400 hasPublicationYear "2019" @default.
- W2968953400 type Work @default.
- W2968953400 sameAs 2968953400 @default.
- W2968953400 citedByCount "101" @default.
- W2968953400 countsByYear W29689534002019 @default.
- W2968953400 countsByYear W29689534002020 @default.
- W2968953400 countsByYear W29689534002021 @default.
- W2968953400 countsByYear W29689534002022 @default.
- W2968953400 countsByYear W29689534002023 @default.
- W2968953400 crossrefType "journal-article" @default.
- W2968953400 hasAuthorship W2968953400A5010925062 @default.
- W2968953400 hasAuthorship W2968953400A5015591858 @default.
- W2968953400 hasAuthorship W2968953400A5017574713 @default.
- W2968953400 hasAuthorship W2968953400A5035218748 @default.
- W2968953400 hasAuthorship W2968953400A5043585994 @default.
- W2968953400 hasAuthorship W2968953400A5045732752 @default.
- W2968953400 hasAuthorship W2968953400A5055462512 @default.
- W2968953400 hasAuthorship W2968953400A5056205361 @default.
- W2968953400 hasAuthorship W2968953400A5058733601 @default.
- W2968953400 hasAuthorship W2968953400A5061237827 @default.
- W2968953400 hasAuthorship W2968953400A5062013948 @default.
- W2968953400 hasAuthorship W2968953400A5064953304 @default.
- W2968953400 hasAuthorship W2968953400A5075799959 @default.
- W2968953400 hasAuthorship W2968953400A5078252133 @default.
- W2968953400 hasAuthorship W2968953400A5081099179 @default.
- W2968953400 hasBestOaLocation W29689534002 @default.
- W2968953400 hasConcept C121608353 @default.
- W2968953400 hasConcept C126322002 @default.
- W2968953400 hasConcept C141071460 @default.
- W2968953400 hasConcept C143998085 @default.